BTA-1

Target: This ligand targets amyloid-beta aggregates rather than a single soluble protein target in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for amyloid-beta aggregates rather than a single soluble protein target. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings amyloid-beta aggregates rather than a single soluble protein target into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated BRD Degradation: BTA-1 can be used as a targeting ligand in PROTAC designs to recruit an E3 ligase and drive selective degradation of BRD family bromodomain proteins. This application supports mapping degrader potency, degradation kinetics, and dose–response behavior, enabling structure–activity optimization for improved target engagement and sustained protein loss.

• E3 Ligase Recruitment Optimization: Incorporating BTA-1 into PROTAC scaffolds allows systematic evaluation of different E3 ligase recruiters and linker architectures. Researchers can compare ternary complex formation, ubiquitination efficiency, and degradation selectivity to identify configurations that maximize productive ubiquitin transfer while minimizing off-target degradation.

• Target Engagement and Mechanism Studies: BTA-1-based PROTACs are suitable for dissecting degradation mechanisms through assays that distinguish binding-driven effects from ubiquitin–proteasome–dependent turnover. Experiments such as proteasome inhibition, time-resolved degradation profiling, and competition with parent ligands help clarify whether observed loss reflects efficient chimeric recruitment and productive ternary complex formation.

• Proteome-Wide Selectivity Profiling: Using BTA-1 in PROTAC research enables evaluation of selectivity across bromodomain-containing proteins and related pathways. Quantitative proteomics can assess degradation breadth, identify compensatory responses, and refine ligand and linker choices to achieve narrower target spectra, improving mechanistic confidence in BRD-directed targeted protein degradation.

BTA-1 is listed as a potential target-protein ligand, but a reliable target assignment for PROTAC design was not confirmed from the supplied identifiers. Use should be restricted to cases where independent binding data are available. This molecule is described in detail below.

Structure: The structure of BTA-1 is characterized by primary or secondary amine/basic nitrogen centers; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.